IBRX
Immunitybio Inc
$
2.560
- Overview
- Forecast
- Valuation
- Earnings
Line
|
Candle
1D
5D
1M
3M
6M
YTD
1Y
5Y
High
2.670
Open
2.580
VWAP
--
Vol
7.09M
Mkt Cap
2.26B
Low
2.540
Amount
--
EV/EBITDA(TTM)
--
Total Shares
691.57M
EV
2.96B
EV/OCF(TTM)
--
P/S(TTM)
60.39
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
Show More
Market Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2025Q3
FY2025Q2
33.01M
+337.1%
--
--
27.85M
+356.07%
--
--
21.95M
+1996.47%
--
--
Estimates Revision
The market is revising Downward the revenue expectations for ImmunityBio, Inc. (IBRX) for FY2025, with the revenue forecasts being adjusted by -5.11% over the past three months. During the same period, the stock price has changed by 1.99%.
Revenue Estimates for FY2025
Revise Downward
-5.11%
In Past 3 Month
Stock Price
Go Up
+1.99%
In Past 3 Month
3 Analyst Rating
147.27% Upside
Wall Street analysts forecast IBRX stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for IBRX is 6.33 USD with a low forecast of 5.00 USD and a high forecast of 8.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Buy
0 Hold
0 Sell
Strong Buy
147.27% Upside
Current: 2.560
Low
5.00
Averages
6.33
High
8.00
147.27% Upside
Current: 2.560
Low
5.00
Averages
6.33
High
8.00
Piper Sandler
Neutral -> Overweight
upgrade
$5
2025-05-20
Reason
Piper Sandler
Price Target
$5
2025-05-20
upgrade
Neutral -> Overweight
Reason
Piper Sandler upgraded ImmunityBio to Overweight from Neutral with a price target of $5, up from $4.25.
Piper Sandler
Neutral -> Overweight
upgrade
$5
2025-05-20
Reason
Piper Sandler
Price Target
$5
2025-05-20
upgrade
Neutral -> Overweight
Reason
Piper Sandler upgraded ImmunityBio to Overweight from Neutral with a price target of $5, up from $4.25, following a transfer of coverage. The company is developing Anktiva, t-haNK and M-ceNK cell therapies and DNA vaccines to restore the immune system's ability to kill cancer, the analyst tells investors in a research note. The firm says Anktiva is off to a strong launch in non-muscle invasive bladder cancer, with sales forecast of $83.5M in 2025. Piper sees multiple label expansion opportunities despite the refusal to file letter issued by the FDA for Anktiva in non-muscle invasive bladder cancer that is unresponsive to treatment with Bacillus Calmette-Guerin.
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$30
2025-04-23
Reason
D. Boral Capital
Jason Kolbert
Price Target
$30
2025-04-23
Maintains
Strong Buy
Reason
HC Wainwright & Co.
Andres Maldonado
Strong Buy
Reiterates
$8
2025-04-16
Reason
HC Wainwright & Co.
Andres Maldonado
Price Target
$8
2025-04-16
Reiterates
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$30
2025-04-15
Reason
D. Boral Capital
Jason Kolbert
Price Target
$30
2025-04-15
Maintains
Strong Buy
Reason
D. Boral Capital
Jason Kolbert
Strong Buy
Maintains
$30
2025-04-09
Reason
D. Boral Capital
Jason Kolbert
Price Target
$30
2025-04-09
Maintains
Strong Buy
Reason
See All Ratings
Valuation Metrics
The current forward P/E ratio for Immunitybio Inc (IBRX.O) is -5.60, compared to its 5-year average forward P/E of -7.93. For a more detailed relative valuation and DCF analysis to assess Immunitybio Inc 's fair value, click here.
Forward PE
The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
N/A
5Y Average PE
-7.93
Current PE
-5.60
Overvalued PE
-0.64
Undervalued PE
-15.23
Forward EV/EBITDA
The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
N/A
5Y Average EV/EBITDA
0.00
Current EV/EBITDA
0.00
Overvalued EV/EBITDA
0.00
Undervalued EV/EBITDA
0.00
Forward PS
The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
N/A
5Y Average PS
10080.28
Current PS
21.21
Overvalued PS
28007.05
Undervalued PS
-7846.50
Financials
Annual
Quarterly
FY2025Q1
YoY :
+41192.50%
16.52M
Total Revenue
FY2025Q1
YoY :
-32.32%
-64.43M
Operating Profit
FY2025Q1
YoY :
-3.33%
-129.67M
Net Income after Tax
FY2025Q1
YoY :
-25.00%
-0.15
EPS - Diluted
FY2025Q1
YoY :
-19.60%
-87.03M
Free Cash Flow
FY2025Q1
YoY :
-0.35%
99.65
Gross Profit Margin - %
FY2025Q1
YoY :
-99.12%
-1.21K
FCF Margin - %
FY2025Q1
YoY :
-99.77%
-785.05
Net Margin - %
Trading Trends
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Hedge Fund
Hedge Funds are Neutral. There are no significant trading trends over the last quarter.
Sold
0-3
Months
0.0
Volume
0
3-6
Months
0.0
Volume
0
6-9
Months
0.0
Volume
0
0-12
Months
0.0
Volume
0
Bought
0-3
0
0.0
Volume
Months
3-6
0
0.0
Volume
Months
6-9
3
4.4M
Volume
Months
0-12
0
0.0
Volume
Months
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
0-3
Months
0.0
USD
0
3-6
Months
0.0
USD
0
6-9
Months
0.0
USD
0
0-12
Months
0.0
USD
0
Bought
0-3
0
0.0
USD
Months
3-6
0
0.0
USD
Months
6-9
0
0.0
USD
Months
0-12
0
0.0
USD
Months
IBRX News & Events
Events Timeline
2025-07-25 (ET)
2025-07-25
06:06:46
ImmunityBio announces $80M registered direct offering
2025-07-25
06:05:31
ImmunityBio reports Q2 revenue $26.4M, consensus $21.95M
2025-06-02 (ET)
2025-06-02
09:23:36
ImmunityBio receives FDA Expanded Access authorization for Cancer BioShield
Sign Up For More Events
Sign Up For More Events
News
4.5
07-25NASDAQ.COMAfter Hours Most Active for Jul 25, 2025 : GRAB, TRI, IBRX, VZ, PFE, PCG, T, INTC, NVDA, INDV, CRH, MAGN
4.0
07-25BenzingaD. Boral Capital Maintains Buy on ImmunityBio, Maintains $30 Price Target
8.5
07-25NewsfilterImmunityBio, Inc. Announces Execution of $80 Million Equity Financing from Multiple Institutional Investors
Sign Up For More News
People Also Watch
WSBC
WesBanco Inc
30.510
USD
-4.12%
EFSC
Enterprise Financial Services Corp
55.380
USD
-2.19%
PACS
Pacs Group Inc
11.220
USD
-2.69%
AVDX
Avidxchange Holdings Inc
9.860
USD
0.00%
RVLV
Revolve Group Inc
20.940
USD
+0.19%
PAGS
PagSeguro Digital Ltd
7.890
USD
-0.63%
PLUS
ePlus inc
67.120
USD
-2.14%
TFIN
Triumph Financial Inc
58.060
USD
-4.49%
CHEF
Chefs' Warehouse Inc
66.920
USD
+8.71%
VSTS
Vestis Corp
6.110
USD
-3.63%
FAQ
What is Immunitybio Inc (IBRX) stock price today?
The current price of IBRX is 2.56 USD — it has increased 0.79 % in the last trading day.
What is Immunitybio Inc (IBRX)'s business?
What is the price predicton of IBRX Stock?
What is Immunitybio Inc (IBRX)'s revenue for the last quarter?
What is Immunitybio Inc (IBRX)'s earnings per share (EPS) for the last quarter?
What changes have occurred in the market's expectations for Immunitybio Inc (IBRX)'s fundamentals?
How many employees does Immunitybio Inc (IBRX). have?